N@N

HEMISPHERX BIOPHARMA INC (AMEX:HEB), Down By 6.06% ($0.02) From $0.330 After BUYINS.NET Report Predicted Weakness Before Earnin

^{Published on 2012-05-02 07:40:27 - WOPRAI}
 

May 2, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, April 24th 2012 stating that HEMISPHERX BIOPHARMA INC (AMEX:HEB) was expected to be Down Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=heb&id=267281

At the time this story was written, HEMISPHERX BIOPHARMA INC (AMEX:HEB) is Down By 6.06% ($0.02) From $0.330 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

HEMISPHERX BIOPHARMA INC (AMEX:HEB) - Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The companys products include Ampligen, an experimental drug that is under clinical development for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, Hepatitis B, human immunodeficiency virus, renal cell carcinoma, and malignant melanoma; and Alferon N Injection for the treatment of genital warts. Its products also comprise Alferon LDO, a low-dose, oral liquid formulation of natural alpha interferon for influenza and other emerging viral diseases; and Oragens, a set of oral broad spectrum antivirals and immunological enhancers for the treatment of chronic viral and immunological disorders. The company has a strategic alliance with Accredo to develop certain marketing and distribution capacities for Ampligen in the United States. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. HEMISPHERX BIOPHARMA INC (AMEX:HEB) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net